Literature DB >> 28821433

ABCB5 promotes melanoma metastasis through enhancing NF-κB p65 protein stability.

Shenghao Wang1, Li Tang2, Junyu Lin3, Zhongliang Shen4, Yikun Yao5, Wei Wang3, Shuai Tao3, Chenjian Gu3, Jie Ma6, Youhua Xie7, Yanfeng Liu8.   

Abstract

Melanoma is the most aggressive type of skin cancer. Melanoma has an extremely poor prognosis because of its high potential for vascular invasion, metastasis and recurrence. The mechanism of melanoma metastasis is not well understood. ATP-binding cassette sub-family B member 5 (ABCB5) plays a key role in melanoma growth. However, it is uncertain what function ABCB5 may exert in melanoma metastasis. In this report, we for the first time demonstrate ABCB5 as a crucial factor that promotes melanoma metastasis. ABCB5 positive (ABCB5+) malignant melanoma initiating cells (MMICs) display a higher metastatic potential compared with ABCB5 negative (ABCB5-) melanoma subpopulation. Knockdown of ABCB5 expression reduces melanoma cell migration and invasion in vitro and melanoma pulmonary metastasis in tumor xenograft mice. ABCB5 and NF-κB p65 expression levels are positively correlated in both melanoma tissues and cell lines. Consequently, ABCB5 activates the NF-κB pathway by inhibiting p65 ubiquitination to enhance p65 protein stability. Our finding highlights ABCB5 as a novel pro-metastasis factor and provides a potential therapeutic target for melanoma.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ABCB5; Malignant melanoma initiating cells; Melanoma; Metastasis

Mesh:

Substances:

Year:  2017        PMID: 28821433     DOI: 10.1016/j.bbrc.2017.08.052

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

Review 1.  Heterogeneity in Melanoma.

Authors:  Mei Fong Ng; Jacinta L Simmons; Glen M Boyle
Journal:  Cancers (Basel)       Date:  2022-06-20       Impact factor: 6.575

Review 2.  Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2017-11-20

3.  Hepatic toxicity following actinomycin D chemotherapy in treatment of familial gestational trophoblastic neoplasia: A case report.

Authors:  Xiyan Mu; Rutie Yin; Danqing Wang; Liang Song; Yu Ma; Xia Zhao; Qingli Li
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

Review 4.  Signaling of Tumor-Derived sEV Impacts Melanoma Progression.

Authors:  Aneta Zebrowska; Piotr Widlak; Theresa Whiteside; Monika Pietrowska
Journal:  Int J Mol Sci       Date:  2020-07-17       Impact factor: 5.923

Review 5.  Research Progress of Cancer Stem Cells in Uveal Melanoma.

Authors:  Yu Ning Chen; Yang Li; Wen Bin Wei
Journal:  Onco Targets Ther       Date:  2020-11-27       Impact factor: 4.147

Review 6.  Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions.

Authors:  Nuno Jorge Lamas; Arnaud Martel; Sacha Nahon-Estève; Samantha Goffinet; Adam Macocco; Corine Bertolotto; Sandra Lassalle; Paul Hofman
Journal:  Cancers (Basel)       Date:  2021-12-25       Impact factor: 6.639

7.  17-Aminogeldanamycin Inhibits Constitutive Nuclear Factor-Kappa B (NF-κB) Activity in Patient-Derived Melanoma Cell Lines.

Authors:  Mariusz L Hartman; Magdalena Rogut; Aleksandra Mielczarek-Lewandowska; Michal Wozniak; Malgorzata Czyz
Journal:  Int J Mol Sci       Date:  2020-05-26       Impact factor: 5.923

Review 8.  Oral Cancer Stem Cells: Therapeutic Implications and Challenges.

Authors:  Linah A Shahoumi
Journal:  Front Oral Health       Date:  2021-07-21

9.  Identification of genes and pathways leading to metastasis and poor prognosis in melanoma.

Authors:  Xin Zhang; Wandong Wang; Yun Wang; Guan Jiang
Journal:  Aging (Albany NY)       Date:  2021-09-28       Impact factor: 5.682

10.  Resistance to drugs and cell death in cancer stem cells (CSCs).

Authors:  Ahmad R Safa
Journal:  J Transl Sci       Date:  2019-06-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.